Background: Diabetes mellitus (DM) is a collection of metabolic illnesses marked by a persistent hyperglycemic state caused by insulin production, insulin action, or both. Objectives: Present Study is designed to evaluate the anti-diabetic activities of some new heterocyclic compounds in albino rat. Methods: A total of 50 adult male albino rats were classified into five groups. Group I (negative control group, rats orally administered 1 ml saline daily).Group II (diabetic group, animals were injected intraperitoneally with 60 mg/kg b.wt streptozotocin).Group III (compound 1 group, diabetic animals treated with 50 mg/kg b.wt of Potassium salt of benzimidazole-2-carboxaldehyde semicarbazone for 40 day orally).Group IV (compound 2 group, diabetic rats treated with 50 mg /kg b.wt of Potassium salt of benzimidazole-2-carboxaldehyde thiosemicarbazone for  40 day orally).Group V (metformin group, diabetic rats treated with 100 mg /kg b.wt of metformin for  40 day orally). Results: Oral administration of new synthesized benzimidazole derivatives compounds ameliorated all biochemical parameters (ALT, AST ALB, T.Bili, urea, creatinine, CK-MB and LDH) and enhanced activity of antioxidant enzymes. Also, decrease Myostatin levels when compared with diabetic rats. Molecular docking studies confirmed binding of compounds with Myostatin protein in terms of energy and revealed of the existence of hydrogen bond, hydrophobic interaction. Our results were confirmed by histopathological examination of liver, kidney and pancreatic tissues. Conclusion: this study suggests that new synthesized benzimidazole derivatives compounds exhibit anti diabetic and antioxidant activity in streptozotocin- induced diabetic rats.